# A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamo

Source: https://onco.cc/trials/nct07824882/  
OnCo record `nct07824882` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of adebrelimab in lung cancer, run by Hansoh BioMedical R&D Company, not yet recruiting.

## Summary

A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations is a phase 2, randomised interventional study registered as NCT07824882 by Hansoh BioMedical R&D Company, with a registry enrolment figure of 76 participants, started 2026-09-10 and due to reach its primary completion in 2028-03-30. Interventions recorded: HS-20093 for Injection; Adebrelimab Injection. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Objective Response Rate (ORR); Progression-Free Survival (PFS). Lung eligibility wording from the registry: "Previously treated patients with histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07824882
- Phase: 2
- Setting: A Multicenter, Randomized, Open-Label, Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
- Sponsor: Hansoh BioMedical R&D Company
- Enrolled: 76

## Sources

- ClinicalTrials.gov NCT07824882: https://clinicaltrials.gov/study/NCT07824882

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/)
- companies: [Hansoh Pharmaceutical](https://onco.cc/companies/hansoh-pharma/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07824882.json